lab

EU approves Idelvion for haemophilia B treatment

pharmafile | May 13, 2016 | News story | Medical Communications, Research and Development CSL, EU, Idelvion, approval, haemophilia B 

The European Commission has approved Idelvion, coagulation Factor IX (recombinant) for the treatment and prophylaxis of bleeding in patients with haemophilia B.

Approved in children and adults, the indicated treatment regimen includes routine prophylaxis to prevent or reduce the frequency of bleeding episodes; on demand control; and the perioperative management of bleeding around the time of surgery.

Also recently approved in the US and Canada, Idelvion has demonstrated efficacy in maintaining Factor IX activity levels above 5% in most patients over 14 days.

Advertisement

Dr Andrew Cuthbertson, chief scientific officer at CSL, says: “Idelvion provides excellent bleeding control by maintaining factor IX activity levels above 5% over a prolonged period of time… We look forward to bringing Idelvion to the European market and are particularly excited about the positive impact this long-acting therapy can have on the lives of patients with haemophilia B.”

Sean Murray

Related Content

Sharp invests $100m in US and EU manufacturing and packaging facilities

Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …

Sarclisa recommended for EU approval in newly diagnosed multiple myeloma

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s …

First UK patient treated with CSL Behring’s gene therapy for Haemophilia B

CSL Behring has announced that the first patient in the UK has received HEMGENIX (etranacogene …

The Gateway to Local Adoption Series

Latest content